Summit Therapeutics' Stock Skyrockets After Cancer Drug Outperforms Keytruda in Phase 3 Trial
TL;DR Summary
Summit Therapeutics' stock surged after the company announced that its cancer drug outperformed Keytruda in a Phase 3 trial, just ahead of a major cancer conference in Chicago.
- Summit Therapeutics’ stock soars as biotech says its cancer drug beat Keytruda in Phase 3 Endpoints News
- Why Summit Therapeutics Stock Is Sinking Today Yahoo Finance
- Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China Business Wire
- Pharma Billionaire's Fortune More Than Doubles In A Day On Cancer Drug Trial News Forbes
- Summit Therapeutics’ stock surges as cancer drug vies with Merck’s Keytruda MarketWatch
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
0 min
vs 1 min read
Condensed
50%
56 → 28 words
Want the full story? Read the original article
Read on Endpoints News